Supreme Court questions 16% retailer margin rule after cancer drug sells nearly 10x higher
The court cited a cancer drug supplied for around ₹3,000 and sold for ₹27,000 while questioning whether the DPCO’s 16% retailer margin should apply uniformly to essential medicines. The next hearing is scheduled for October 12, 2026.
The development
The Supreme Court questioned whether the DPCO’s 16% retailer margin should apply uniformly to essential medicines on September 29, 2026, citing a cancer drug supplied for around ₹3,000 and sold for ₹27,000; it scheduled the next hearing for October 12, 2026.
The numbers
- 16%
- 2013
- September 29, 2026
- nearly ten-fold
- around ₹3,000
- ₹27,000
- nearly ₹24,000
- October 12, 2026
- 10 times
Why it matters to operators and investors
Assess exposure to essential-medicine pricing rules in portfolio and deal diligence, while treating any margin-rule change as uncertain pending the hearing.
What to watch next
- Court observations or interim directions at the October 12, 2026 hearing.
- Government or NPPA submissions proposing drug-specific margins, exemptions, or a revised DPCO framework.
- Formal notifications, circulars, or enforcement actions affecting retailer margins.
- Changes in pharmacy stocking, substitution, or reported availability of high-cost essential medicines.
- Avoid assuming an immediate margin reset; keep forecasts based on current rules until an order or formal policy change appears.
- Map exposure by medicine category, especially essential and high-cost drugs, and model the effect of lower or differentiated margins.
- Review supplier contracts and inventory decisions for medicines where price scrutiny could intensify.
- Prepare customer and pharmacist communications that explain any future price or product changes without implying a rule change has already occurred.
The counter-case
The court has only questioned the rule; it has ordered no pricing change, and the October 12, 2026 hearing leaves the outcome and timing uncertain. The ₹3,000-to-₹27,000 example may be an exceptional product or reflect differences in pack size, formulation, or transaction terms, rather than evidence that the 16% rule broadly drives medicine prices. Even if the court narrows the rule, any effect on retailer economics could be limited or offset by changes elsewhere in the supply chain.